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Quantity of clot lysed after catheter-directed
thrombolysis for iliofemoral deep venous
thrombosis correlates with postthrombotic
morbidity
Nina K. Grewal, MD, Jorge Trabal Martinez, MD, Linda Andrews, RN,
and Anthony J. Comerota, MD, Toledo, Ohio
Background: International treatment guidelines now recognize the importance of thrombus removal to reduce post-
thrombotic morbidity when treating patients with extensive acute deep venous thrombosis (DVT). Studies have shown
that thrombus resolution with catheter-directed thrombolysis in patients with iliofemoral DVT reduces postthrombotic
morbidity, although patients unsuccessfully treated with catheter-directed thrombolysis (CDT) do not enjoy the same
long-term benefit. The purpose of this study is to objectively assess whether the amount of clot reduction at the time of
acute therapy correlates with long-term postthrombotic morbidity.
Methods: Forty-two patients who underwent catheter-directed and/or pharmacomechanical lysis of iliofemoral DVTwere
quantitatively evaluated. Patients had their degree of clot lysis quantified and were divided into two main groups for
comparison. Group I (n  33) had >50% clot lysis (mean, 84%) and group II (n  9) had <50% lysis (mean, 42%). At a
mean follow-up interval of 14 months, the degree of chronic venous disease was assessed by evaluators blinded to the
degree of clot lysis. Evaluation of postthrombotic morbidity was performed using the Villalta scale, and the clinical class
of CEAP, and quality-of-life (QOL) was assessed using the Short Form Health Survey (SF-36).
Results: Mean CEAP scores were 0.85 and 3.13 (P  .005), and Villalta scores were 2.38 and 6.25 (P  .009) in group
I and group II, respectively. Patient QOL in group I was higher than group II in all parameters. Physical functioning (P
.035), role physical (P  .012), general health (P  .014), vitality (P < .001), and social functioning (P  .012) were all
significantly better in group I. Bodily pain (P .117), role emotional (P .624), and mental health (P .096) strongly
favored group I patients but did not reach statistical significance.
Conclusion: Patients with extensive DVT treated with catheter-based interventions to eliminate thrombus suffer relatively
little postthrombotic morbidity. The degree of clot lysis directly correlates with long-term outcome. Improved QOL, the
Villalta scale, and clinical class of CEAP are linearly correlated with the amount of clot resolution. (J Vasc Surg 2010;51:
1209-14.)Iliofemoral deep venous thrombosis (DVT) treated
only with anticoagulation results in significant post-
thrombotic morbidity1-3 and recurrence rates similar to
patients with cancer.4 Catheter-directed thrombolysis
(CDT), either alone or combined with mechanical clot
manipulation, has been used with increasing frequency to
reduce thrombus burden and the risk and severity of post-
thrombotic morbidity.5-11 Traditional methods of evaluat-
ing outcome of therapy follow treatment lines, that is,
results are reported according to the type of therapy pa-
tients receive, not whether acute treatment had achieved its
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doi:10.1016/j.jvs.2009.12.021intended goal. It seems intuitive that in patients treated
with a procedure designed to eliminate clot, quantitative
clot clearance should be the measure by which patient
benefit is assessed. A preliminary observation by Mewissen
et al5 suggested that venous patency at 1 year was related to
the degree of early clot lysis. However, validated measures
of postthrombotic morbidity have not yet been used to
correlate patient outcome with thrombus resolution after
CDT.
Postthrombotic morbidity can be assessed using an
objective validated instrument, the Villalta scale, which
assesses signs and symptoms.12 Quality of life (QOL) can
be assessed using the Short Form Health Survey (SF-
36),13,14 and the clinical class of the CEAP15 guidelines
provide an objective picture of the clinical severity of
chronic venous disease. These objective measures were
studied in patients who underwent CDT for iliofemoral
DVT, many of whom presented with the clinical picture of
phlegmasia cerulea dolens (swollen, blue, painful limb).
The purpose of this study is to assess whether the
quantity of clot lysis at the end of treatment with catheter-
based techniques for patients with iliofemoral DVT bore
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morbidity and patients’ QOL during follow-up.
PATIENTS AND METHODS
A retrospective review of 44 patients with symptomatic
acute iliofemoral DVTwho were treated with CDT and/or
pharmacomechanical thrombolysis (PMT) at a single insti-
tution between August 2002 and November 2008 was
performed. The majority of patients presented with a swol-
len, bluish, discolored, and painful lower extremity (phleg-
masia cerulea dolens). Two patients were removed from
analysis because they had severe preexisting chronic venous
disease that could interfere with assessment of post-
thrombotic signs and symptoms. One had severe bilateral
lower extremity edema from nephrotic syndrome and pre-
vious DVT. The second patient also had preexisting post-
thrombotic syndrome.
The study was approved by the Institutional Review
Board and all patients signed an informed consent. DVT
was initially diagnosed by duplex ultrasound scan and con-
firmed with phlebography. Eleven patients underwent
CDT alone and 31 had PMT with or without adjunctive
CDT. All patients were treated with recombinant tissue
plasminogen activator (r-tPA) at a dose of 1 mg/hour. If
multiple catheters were used simultaneously, the dose was
increased to 2 mg/hour, infused in a volume of 50-100
cc/hour. Multiside-hole catheters were used for CDT and
the Trellis-8 (Covidien, Mansfield, Mass), AngioJet
(MEDRAD Interventional/Possis, Warrendale, Pa), and
EKOS (EKOS Corp, Bothell, Wash) catheters were used
for PMT. At the completion of lytic therapy, patients were
placed on heparin (unfractionated heparin IV weight-
adjusted and PTT-adjusted protocol or weight-adjusted
low-molecular-weight heparin), and warfarin therapy was
initiated with a target international normalized ratio (INR)
of 2.5. The duration of anticoagulation was continued at
least for 1 year or longer if patients had idiopathic DVT.
Long-leg wraps were used early in the patient’s hospitaliza-
tion, and ambulation was initiated after the interventional
procedures were completed. Elastic compression stockings
at 30-40 mm Hg ankle-gradient were prescribed for all
patients. When patients returned for follow-up, outcome
measures were obtained. The range of follow-up was 1-76
months, with a mean of 14 months. The follow-up evalu-
ation was completed by individuals blinded to the degree of
clot lysis.
The postthrombotic syndrome (PTS) was assessed us-
ing the Villalta scale, which consists of five patient-rated
venous symptoms (pain, cramps, heaviness, paresthesia,
and pruritus) and six clinician-rated physical signs (pretibial
edema, skin induration, hyperpigmentation, pain during
calf compression, venous ectasia, and redness). Each are
rated on a four-point scale (0  none, 1  mild, 2 
moderate, 3  severe). Points are totaled to produce an
overall score (range, 0-33). Subjects were classified as hav-
ing PTS if their score was5 or if a venous ulcer developed
in the leg with DVT.11 The Villalta scale is a reliable,
validated, and responsive measure of PTS.12All patients completed the SF-36 questionnaire evalu-
ating QOL. This instrument examines eight parameters of
QOL and produces two summary measures, with a total
possible score of 100. The results of each study patient were
matched and compared with the responses of healthy sub-
jects with no venous disease, adjusted for age and gender
using norm-based scoring.
Each patient also received a clinical CEAP score, which
evaluates evidence of chronic venous disease based on
clinical classification, etiology, anatomical distribution, and
pathophysiology. Our study focused on the clinical classi-
fication aspect, with scores ranging from C0 (no evidence
of venous disease) to C6 (active venous ulceration).
Each patient’s treatment and posttreatment phlebo-
grams were analyzed to determine the degree of clot lysis
using a modification of the venous scoring method de-
scribed by Mewissen et al5 and previously reported by
Martinez et al.16 Nine venous segments (inferior vena cava,
common iliac, external iliac, common femoral, proximal
portion of the femoral, distal portion of the femoral, pop-
liteal, tibial, and profunda femoris) were evaluated and
scored as follows: 0 indicates a thrombus-free (patent)
segment; 1 represents a50% luminal reduction by throm-
bus and/or stenosis; 2 represents50% luminal reduction;
and 3 indicates an occluded segment. Quantity of clot lysed
was determined by subtracting the posttreatment throm-
bus score from the pretreatment thrombus score and divid-
ing by the pretreatment score.
Based on their final score, patients were stratified into
two groups: group I had50% of their clot lysed and group
II had 50% clot lysed. The SF-36 responses, Villalta
scores, and CEAP clinical classification scores were then
compared between the two groups of patients. The SF-36
results of each patient group were also compared to the
general “healthy” US population using norm-based scor-
ing.17
Statistical analysis. Baseline characteristics, Villalta,
CEAP, and SF-36 survey scores for each lysis group were
compared using t-test, Fisher’s exact test, and nonparamet-
ric tests when appropriate. The SF-36 scores were trans-
formed to a linear scale with a mean of 50 and SD of 10.17
All analyses were performed with SAS software, version 9.2
(SAS Institute Inc, Cary, NC).
RESULTS
Thirty-three patients were classified in group I with
50% clot lysis (mean 84% clot resolution) and 9 patients
having 50% (mean 42% clot resolution) in group II.
There were 17 men and 16 women in group I, with a mean
age of 47 years, and 6 men and 3 women comprised group
II, with a mean age of 44 years.
Clinical assessment. In group I, the mean Villalta
score was 2.38 compared to a mean of 6.25 in group II
(P  .009; Fig 1). The mean CEAP clinical classification
score was 0.85 in group I and 3.13 in group II (P  .005;
Fig 2).
QOL Short Form Health Survey. Patient QOL in
group I was higher than group II in all parameters. Physical
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health (P  .014), vitality (P  .001), and social function-
ing (P .012) were all significantly better in group I (Fig 3;
Table I). Bodily pain (P  .117), role emotional (P 
.624), andmental health (P .096) strongly favored group
I patients but did not reach statistical significance. The
mean physical component score was 49.1 in group I com-
pared to 36.9 in group II (P .014), and the mean mental
component score was 49.9 and 43.9 (P  .20) in group I
and group II, respectively.
The scores of group I and group II patients were
significantly different from age- and gender-matched con-
trols (Table II). Although group I patients did better than
group II, it is evident that patients with acute DVT do not
achieve the same QOL as subjects without DVT, even if
Fig 1. Graph showing the Villalta scores plotted by percent of
clot lysed. Patients with better clot resolution had lower Villalta
scores (P  .11).
Fig 2. CEAP scores of patients plotted by percent of clot lysed.
Improved clot lysis correlated with improved clinical class of CEAP
(P  .057).treated successfully with a strategy of thrombus removal.DISCUSSION
Postthrombotic morbidity after anticoagulation for
acute DVT is reported to occur in 25% to 46% of pa-
tients.18,19 This represents all patients with DVT, not just
those with iliofemoral DVT. Many patients with small-
volume thrombus and isolated calf DVT have been in-
cluded in these studies of PTS. One would expect that
postthrombotic morbidity would be more frequent and
severe in patients with extensive proximal DVT, and indeed
this observation has been reported.1-3 A number of inves-
tigators have reported that a strategy of thrombus removal
reduces postthrombotic morbidity compared to anticoag-
ulation alone.20-24 Unfortunately, previous reports fail to
correlate long-term outcome with quantity of clot re-
moved.Mewissen et al5 quantified the degree of clot lysis in
Fig 3. Graph illustrates the Short Form Health Survey (SF-36)
results of patient groups I and II compared to the general
“healthy” US population using norm-based scoring. Group II
scored lower than group I in all measures of quality of life (QOL)
but role emotional. BP, Bodily pain; GH, general health; MCS,
mental component score; MH, mental health; PCS, physical com-
ponent score; PF, physical functioning; RE, role emotional; RP,
role physical; SF, social functioning; VT, vitality.






(n  9) P value
Physical functioning 48.1 37.3 .035
Role physical 48.5 35.8 .013
Bodily pain 51.0 43.5 .117
General health 49.0 39.0 .014
Vitality 51.7 36.2 .001
Social functioning 49.0 38.4 .038
Role emotional 48.3 46.0 .624
Mental health 49.9 42.9 .966
Physical component 49.2 36.9 .014
Mental component 49.9 43.9 .197
SF-36, Short Form Health Survey.patients entered into the National Venous Registry and
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patency. Comerota et al25 reported that patients in the
venous registry with iliofemoral DVT who had greater than
50% of their clot lysed had a better QOL than those who
were considered lytic failures (50%) and significantly bet-
ter QOL than a cohort-controlled group of patients treated
with anticoagulation alone.
The basic question is whether early clot lysis in patients
with extensive DVT reduces postthrombotic morbidity and
if so, is their benefit related to the quantity of clot lysed?
This paper does not directly address the first question,
because there was not a control group of patients treated
with anticoagulation alone. However, postthrombotic
morbidity was low in most patients in this series, much
lower than would have been expected if patients were
treated with anticoagulation alone. Most enjoyed a good
QOL. However, there was clear evidence that the greater
the degree of clot lysis, the better the patient outcome.
The QOL in patients with quantitatively greater clot
lysis was improved. Patients’ vitality, general health, physi-
cal role functioning, and social functioning were all im-
proved, as were their mean physical component scores.
Although some of these measures did not reach statistical
significance, this likely represents the small sample size. The
differences between patients, however, were clinically
meaningful, as reflected in the Villalta score and CEAP
classification.
The degree of early clot resolution correlates with
long-term benefit. When the Villalta scale is used to define
postthrombotic syndrome, the patients with greater
thrombus resolution had the lowest Villalta score. On the
other hand, patients who had the majority of their clot
persisting at the completion of therapy had worse post-
thrombotic morbidity.
One patient in group II who had a poor response to
lytic therapy, with only 33% lytic success, suffers from
venous ulceration 4 years after treatment and has a Villalta
score of 12. This underscores the importance of striving for
Table II. SF-36 measures of QOL for each group













functioning 54.7 48.1 .001 37.3 .001
Role physical 54.7 48.5 .001 35.8 .001
Bodily pain 56.3 51.0 .001 43.5 .001
General health 55.4 49.0 .001 39.0 .001
Vitality 54.4 51.7 .073 36.2 .001
Social functioning 54.1 49.0 .001 38.4 .001
Role emotional 52.9 48.3 .001 46.0 .008
Mental health 53.0 49.9 .022 42.9 .001
Physical
component 55.8 49.2 .001 36.9 .001
Mental
component 52.5 49.9 .053 43.9 .001
QOL, Quality of life; SF-36, Short Form Health Survey.high lytic success in these patients. One patient in group IIwho had an uncorrected stenosis of a left common iliac vein
stenosis developed a recurrent DVT during follow-up, was
restarted on anticoagulation without any attempt at throm-
bus removal, and developed severe PTS. The patient sub-
sequently underwent iliac vein venoplasty and stenting to
recanalize a chronically occluded common iliac vein.
When the SF-36 QOL outcomes of group I and group
II were compared to age- and gender-matched controls,
there remained significant differences with each group.
This is not surprising, because the SF-36 is not a disease-
specific QOL instrument. Acute DVT, especially extensive
DVT, alters the lives of all patients, even if they do not
develop postthrombotic morbidity. This study confirms
that fact, while at the same time demonstrating improved
QOL, which was linearly correlated with the amount of
clot resolution or, conversely, worse QOL and greater
postthrombotic morbidity in patients with large residual
thrombus burden.
This study adds support to the hypothesis that early
thrombus removal is beneficial to long-term outcome in
patients with iliofemoral DVT. It underscores the impor-
tance of thrombus resolution and correction of underlying
venous lesions followed by therapeutic anticoagulation to
prevent recurrence. It also emphasizes the need for physi-
cians to be persistent in their attempts to clear the venous
system of clot and not terminate their procedure prema-
turely once a strategy of thrombus removal is initiated,
especially if clot resolution is ongoing.
This study has a number of weaknesses. It is retrospec-
tive, and it does not have a control group of similar patients
treated with anticoagulation alone. Also, the number of
patients in group II (50% lysis) is small, thereby making
the comparison less robust. However, as a cohort, these
patients with extensive DVT represent a high-risk group for
severe postthrombotic morbidity, many of whom were
referred because of severe and persisting symptoms after
treatment with standard measures of systemic anticoagula-
tion and leg elevation.
All of the patients in this report were assessed with three
validated outcome measures by individuals unaware of the
degree of clot lysis. A 14-month mean follow-up may be
considered short when assessing postthrombotic syndrome
after acute DVT. However, it is established that the pa-
tients’ postthrombotic condition 6 months after acute
treatment reflects long-term outcome. Furthermore, Kahn
et al,26 in their prospective analysis of patients treated
for acute DVT, reported that patients’ 1-month post-
thrombotic symptoms were predictive of long-term out-
come. It has been our experience that the 6-month
follow-up visit reflected long-term clinical outcome unless
patients suffered recurrent thrombosis, in which case their
postthrombotic symptoms would worsen. Recurrence was
unlikely if patients were properly anticoagulated.
From the initiation of treatment, all patients received
therapeutic anticoagulation and elastic compression. Ini-
tially, patients were wrapped from toes to thigh with snug
elastic compression and ambulated soon after the interven-
tional procedures were completed. Patients were subse-
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compression stockings. Both of these measures have been
shown to improve patient outcomes and reduce post-
thrombotic morbidity. Randomized trials have demon-
strated that early compression with ambulation and com-
pression stockings of 30-40 mmHg ankle-gradient applied
early in the course of treatment and continued long term
reduced postthrombotic morbidity by 50%.27-30
Randomized trials are underway assessing anticoagula-
tion alone vs catheter-directed thrombolysis in patients
with acute DVT. The CaVent trial performed by European
investigators is nearing completion.31 Preliminary informa-
tion indicates improved venous patency is observed in
patients treated with catheter-directed thrombolysis.32 The
Acute Venous Thrombosis: Thrombus Removal with Ad-
junctive Catheter-Directed Thrombolysis (ATTRACT)
trial, an National Institutes of Health (NIH)-funded study,
which will stratify nearly 700 patients with iliofemoral and
infrainguinal DVT, has just begun.33 The ATTRACT trial
will focus on objective measures of patient outcome, similar
to those reported in this study.
Until results of randomized trials demonstrate other-
wise, current data support adopting a strategy of thrombus
removal in patients with iliofemoral DVT, most of whom
present with phlegmasia cerulea dolens. The majority of
patients will be eligible for catheter-based techniques. In
institutions where the ATTRACT trial is being performed,
patients should be randomized to provide additional
level-1 evidence to answer this important question. Other-
wise, in institutions not participating in the ATTRACT
trial, patients should be offered a strategy of thrombus
removal with the goal of eliminating as much thrombus as
possible to minimize postthrombotic morbidity.
The authors acknowledge the expert assistance ofMari-
lyn Gravett in the preparation of this manuscript.
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